ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have received an average rating of “Moderate Buy” from the seventeen analysts that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $24.00.

ACAD has been the topic of a number of recent research reports. StockNews.com lowered ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Values First Advisors Inc. bought a new stake in ACADIA Pharmaceuticals in the 3rd quarter valued at $27,000. Virtus Fund Advisers LLC bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at about $39,000. R Squared Ltd acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth about $47,000. Quest Partners LLC lifted its stake in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,047 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth about $64,000. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Price Performance

ACAD opened at $19.34 on Friday. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of 24.79 and a beta of 0.37. The business’s 50-day moving average price is $18.37 and its two-hundred day moving average price is $16.81. ACADIA Pharmaceuticals has a 1 year low of $14.15 and a 1 year high of $25.20.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.